Ligand Pharmaceuticals Sees Q4 EPS $0.31-$0.32 vs $0.22-$0.24; Q4 Revenue $14.0M-$14.5M vs $11.0M-$12.0M

Ligand Pharmaceuticals Incorporated

is revising upward its previous revenue and net income guidance for the fourth quarter and full year 2013 as a result of higher-than-expected sales of Captisol® material. Ligand now expects total revenues for the fourth quarter of 2013 to be between $14.0 million and $14.5 million, compared with previous guidance of between $11.0 million and $12.0 million. Non-GAAP earnings from continuing operations per diluted share for the fourth quarter of 2013 is expected to be between $0.31 and $0.32, compared with previous guidance of between $0.22 and $0.24. For the full year 2013, Ligand expects total revenues to be between $48.0 million and $48.5 million, compared with previous guidance of